We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.06 | 0.76% | 7.97 | 7.95 | 8.00 | 8.08 | 7.90 | 7.96 | 2,135,086 | 21:19:41 |
From May 2019 to May 2024
By Chris Wack
Ionis Pharmaceuticals Inc. (IONS) said Wednesday it has been notified by its partner, Bayer AG (BAYN.XE), about its decision to advance Ionis-FXI-L(Rx) following positive clinical results.
Ionis's Ionis-FXI-L(Rx) is an antisense medicine being developed to treat patients with clotting disorders.
Ionis entered into an exclusive license agreement with Bayer in May 2015 to develop and commercialize Ionis' programs for the treatment of clotting disorders.
Ionis said that under the agreement, it has generated more than $185 million to date, including a $10 million milestone payment Ionis earned with Bayer's continuation decision. Ionis said it is eligible to receive additional milestone payments as the medicine advances toward the market, as well as tiered royalties in the low to high twenty percent range on gross margins.
Bayer will now assume all development, regulatory and commercialization activities and costs.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 09, 2019 07:23 ET (11:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
